New insulin vs. Brand-Name: a Head-to-Head test in healthy volunteers
NCT ID NCT07608692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tested how a new insulin injection (USLIN®R) compares to a standard brand (Novolin®R) in 32 healthy men. Each participant received both insulins at different times to measure how quickly and effectively they work. The goal is to see if the new insulin is similar enough to offer a reliable alternative for diabetes care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Human insulin injection (USLIN®R and Novolin®R)
- What this could lead to
- If successful, this study could show that the test insulin works similarly to a well-known brand, potentially offering a new, comparable option for people with diabetes.
- What could go wrong
- This is an early-phase trial in only 32 healthy men, not people with diabetes. Results may not apply to real-world patients, and the test insulin might still differ in safety or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS AND PHARMACODYNAMICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
28 Baofeng Road, Qiaokou District
Wuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.